Erlotinib vs Trastuzumab

Erlotinib vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Erlotinib and Trastuzumab.

Mechanism of Action

Erlotinib: Reversible inhibitor of EGFR (HER1) tyrosine kinase, blocking autophosphorylation.

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Erlotinib — 36 hours; Trastuzumab — 28 days.

Chemical Properties

Molecular Formula: Erlotinib — C22H23N3O4.

Molecular Weight: Erlotinib — 393.4380 g/mol.

Type: Erlotinib — Small molecule; Trastuzumab — Antibody.